Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Given Average Recommendation of “Buy” by Analysts

Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) has received a consensus recommendation of “Buy” from the eight analysts that are presently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, five have assigned a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $30.00.

EYPT has been the topic of a number of analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Eyepoint Pharmaceuticals in a research report on Wednesday, October 8th. TD Cowen upgraded shares of Eyepoint Pharmaceuticals to a “strong-buy” rating in a research note on Friday, December 19th. Royal Bank Of Canada lifted their price target on shares of Eyepoint Pharmaceuticals from $28.00 to $39.00 and gave the company an “outperform” rating in a report on Thursday, November 6th. Cantor Fitzgerald raised shares of Eyepoint Pharmaceuticals to a “strong-buy” rating in a research note on Tuesday, November 25th. Finally, Mizuho set a $28.00 target price on shares of Eyepoint Pharmaceuticals in a research note on Monday, October 20th.

Institutional Trading of Eyepoint Pharmaceuticals

Institutional investors have recently made changes to their positions in the business. Nisa Investment Advisors LLC boosted its stake in Eyepoint Pharmaceuticals by 1,636.5% in the 2nd quarter. Nisa Investment Advisors LLC now owns 2,900 shares of the company’s stock worth $27,000 after purchasing an additional 2,733 shares during the period. State of Alaska Department of Revenue bought a new position in shares of Eyepoint Pharmaceuticals during the third quarter worth $50,000. Russell Investments Group Ltd. bought a new position in shares of Eyepoint Pharmaceuticals during the third quarter worth $76,000. Tower Research Capital LLC TRC grew its stake in Eyepoint Pharmaceuticals by 218.3% during the second quarter. Tower Research Capital LLC TRC now owns 8,700 shares of the company’s stock valued at $82,000 after acquiring an additional 5,967 shares in the last quarter. Finally, R Squared Ltd bought a new stake in Eyepoint Pharmaceuticals in the 2nd quarter valued at $100,000. Hedge funds and other institutional investors own 99.41% of the company’s stock.

Eyepoint Pharmaceuticals Trading Up 0.2%

EYPT opened at $18.29 on Friday. The firm’s 50 day simple moving average is $14.32 and its two-hundred day simple moving average is $12.39. The company has a market capitalization of $1.51 billion, a PE ratio of -6.12 and a beta of 1.67. Eyepoint Pharmaceuticals has a 1-year low of $3.91 and a 1-year high of $19.11.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last posted its quarterly earnings data on Wednesday, November 5th. The company reported ($0.85) EPS for the quarter, missing the consensus estimate of ($0.77) by ($0.08). The company had revenue of $0.97 million during the quarter, compared to analysts’ expectations of $3.33 million. Eyepoint Pharmaceuticals had a negative return on equity of 76.13% and a negative net margin of 485.95%. Equities analysts forecast that Eyepoint Pharmaceuticals will post -2.13 earnings per share for the current fiscal year.

About Eyepoint Pharmaceuticals

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.